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Abstract
Diethanolamine (DEA) is a widely used ingredient in many consumer products and in a number of
industrial applications. It has been previously reported that dermal administration of DEA to mice
diminished hepatic stores of choline and altered brain development in the fetus. The aim of this study
was to use mouse neural precursor cells in vitro to assess the mechanism underlying the effects of
DEA. Cells exposed to DEA treatment (3mM) proliferated less (by 5-bromo-2-deoxyuridine
incorporation) at 48 h (24% of control [CT]), and had increased apoptosis at 72 h (308% of CT).
Uptake of choline into cells was reduced by DEA treatment (to 52% of CT), resulting in diminished
intracellular concentrations of choline and phosphocholine (55 and 12% of CT, respectively). When
choline concentration in the growth medium was increased threefold (to 210μM), the effects of DEA
exposure on cell proliferation and apoptosis were prevented, however, intracellular phosphocholine
concentrations remained low. In choline kinase assays, we observed that DEA can be phosphorylated
to phospho-DEA at the expense of choline. Thus, the effects of DEA are likely mediated by inhibition
of choline transport into neural precursor cells and by altered metabolism of choline. Our study
suggests that prenatal exposure to DEA may have a detrimental effect on brain development.
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Diethanolamine (DEA, CASRN 111−42−2) is an alkanolamine extensively used in many
consumer products (cosmetic formulations and pharmaceuticals), as well as in various
industrial processes (CIR, 1983, 1986). The most common exposure to DEA in humans is via
dermal exposure to personal-care products (i.e., soaps, shampoos, and cosmetics), detergents,
and other surfactants that contain DEA or fatty acid conjugates of DEA (TPMC, 2002).
Occupational exposure to DEA occurs through the use of lubricating liquids in industrial
processes (TPMC, 2002). The National Institute for Occupational Safety and Health estimates
that the number of workers potentially exposed to DEA is approximately 800,000 per year
(TPMC, 2002). Estimated annual production of DEA in the United States was 106,000 tons in
1995 (TPMC, 2002).
Although most of the studies that focused on the potential toxicity of DEA and its potential as
a carcinogen have found no effects in humans (IARC, 2000), there is no available data in
humans regarding tissue levels of DEA or quantifying human exposure to DEA (TPMC,
2002). However, studies performed in rodents found an association between long-term
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exposure to DEA and liver and kidney tumors (Program, 1999). Prolonged DEA administration
to rats resulted in DEA accumulation in various tissues at high concentrations (31 μg equivalent
DEA/g tissue in rat brains after an 8-week exposure to a daily dose of 7 mg/kg bw), with
variable accumulation rates for different tissues (114 vs. 10 tissue per blood ratio in liver and
brain, respectively) (Mathews et al., 1997). Because DEA is structurally similar to choline, it
was hypothesized that DEA-related outcomes are due to perturbations in choline metabolism;
such effects have been demonstrated in liver (Barbee and Hartung, 1979; Lehman-McKeeman
et al., 2002; Stott et al., 2000). Similar to choline deficiency, DEA also alters DNA methylation
in mouse hepatocytes (Bachman et al., 2006).
Maternal choline deficiency during pregnancy altered the development of fetal mouse
hippocampus (Albright et al., 2005; Craciunescu et al., 2003), and this effect was likely
mediated by alterations in gene-specific DNA methylation within neuronal precursor cells that
will form the hippocampus (Niculescu et al., 2004, 2006). We recently reported that DEA,
when dermally administered to pregnant mice, induced similar changes in the fetal
hippocampus, i.e., reduced proliferation of neuronal precursor cells and increased apoptosis
(Craciunescu et al., 2006).
The aim of the present work was to study a potential mechanism for these alterations. Based
on previous studies using in vitro models (Lehman-McKeeman and Gamsky 1999, 2000), we
hypothesized that DEA inhibits uptake of choline in mouse neural precursor cells and results
in diminished intracellular availability of choline. If this occurs, supplementation with choline
should prevent the effects of DEA. This is the first study, in our knowledge, that describes
changes induced by DEA on the metabolism of choline in neural precursor cells.
MATERIALS AND METHODS
All reagents were purchased from Sigma Chemicals (St Louis, MO), unless otherwise
specified, and solvents were of HPLC grade. DEA (ethylene-d8) was obtained from Cambridge
Isotope Laboratories (Andover, MA).
Cell culture
Mouse C57Bl/6J cortical neural precursor cells (at embryonic day 14) were purchased from
Cambrex (Walkersville, MD; # M-Cx-300) and were initially plated according to the
manufacturer's protocol using Neurobasal medium (Invitrogen, Purchase, NY) with the
following ingredients added (Wachs et al., 2003): 1% 2mM L-Glutamine (Invitrogen), 1% 100
U/ml Penicillin-Streptomycin (Invitrogen), 2% B27 Supplement without vitamin A
(Invitrogen), 20 ng/ml murine EGF (Invitrogen), 20 ng/ml human bFGF (Invitrogen), and 2
μg/ml heparin. The medium was filtered into a sterile container using a Nalgene 150 ml SFCA
membrane 0.2 μm filter (Fisher Scientific, Fair Lawn, NJ). Cells were plated in 10 cm petri
dishes (Fisher Scientific) and incubated for 5 days at 37°C and 5% CO2. At day 3, fresh medium
and growth factors were added to double the suspension volume. After 5 days, the culture
medium containing floating neurospheres was collected in sterile 15 ml tubes and centrifuged
at 120g for 5 min at 37°C. The neurosphere pellets were dissociated in Accutase (Innovative
Cell Technologies, San Diego, CA), passaged, and reseeded as a suspension. Cells were treated
for up to 72 h with Neurobasal medium without choline chloride (D700SA; Atlanta Biologicals,
Lawrenceville, GA) containing the above described ingredients but with different
concentrations of choline chloride and DEA (n = 4 plates per treatment): 70μM choline chloride
(control, CT); 210μM choline chloride (choline supplemented, CS); 70μM choline chloride
and 3mM DEA (CT-DEA); 210μM choline chloride and 3mM DEA (choline supplementation
with DEA [CS-DEA]). At the end of 48 and 72 h time exposure, the neurospheres were
harvested and processed immediately, or stored as pellets at − 20°C for the choline and DEA
measurements.
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DEA administration to pregnant mice
DEA (80 mg/kg bw/day) was administered dermally as previously described (Craciunescu et
al., 2006), from gestation day 7 through 17. At the end of day 17, fetal brains were removed,
stored at − 80°C, and subsequently processed for the determination of DEA metabolites. Fetal
brains from two different pregnant dams were used.
Cell proliferation
Cell proliferation was assessed using 5-bromo-2-deoxyuridine (BrdU) incorporation. Prior to
harvesting, 10μM BrdU was added to the culture media and cells were incubated for 2 h. Cells
were harvested and subsequently processed using a BrdU Immunohistochemistry Kit
(Chemicon International, Temecula, CA) according to the manufacturer's protocol. BrdU-
positive cells (cells in the S phase of the cell cycle) were identified using light microscopy and
expressed as a percentage of the total number of cells. At least 300 cells were counted per
sample and datapoint.
DNA fragmentation
Terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate (dUTP)-
digoxigenin anti-digoxigenin fluorescein conjugate antibody nick end labeling (TUNEL) was
used as a marker of apoptosis. Cells with single- and double-stranded DNA breaks were
detected using the ApopTag Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon
International), according to the manufacturer's protocol. Using light microscopy, at least 300
cells were counted per sample and datapoint, and TUNEL-positive cells were expressed as a
percentage of the total number of cells.
Choline uptake
Radiolabeled choline chloride ([methyl-14C]; 55 mCi/mmol, ICN Biomedicals, Irvine, CA)
was used to assess choline uptake into neural precursor cells for all four treatment groups: CT,
CS, CT-DEA, and CS-DEA. Briefly, samples were incubated with 14C-choline (10,000
disintegrations per minute [DPM]), where the total concentration of choline was brought to 70
or 210μM, respectively, with unlabeled choline chloride. After incubating at 37°C for 6 h, cells
were immediately put on ice. All subsequent procedures were performed on ice. To determine
the background caused by extracellular radiolabel, ice-cold media, containing the same amount
of radiolabeled choline as the experiment, was added to cells which, in turn, were immediately
harvested on ice and subjected to centrifugation. Cell pellets were washed with 15 ml PBS
twice, resuspended in distilled water, and sonicated (five pulses using a Sonicator W-225R,
Heat Systems-Ultrasonics, Framingdale, NY). Aliquots from the sonicated samples were used
to determine DNA concentration (Labarca and Paigen, 1980), and radiolabel was counted after
the addition of 3 ml scintillation fluid (ScintiSafe 30%, Fisher Scientific) using a Wallac1409
liquid scintillation counter (PerkinElmer, Boston, MA). DPM values were normalized for DNA
amount, and corrected for extracellular background and specific activity of 14C-choline in the
initial incubation medium for each treatment. Uptake data were expressed as nmol choline per
mg DNA. The external background was less than 3% of the total DPM.
Choline and DEA metabolites
Choline, DEA, and their metabolites were extracted from fetal brains and neural precursor cell
samples (after 48 h treatment) using the method of Bligh and Dyer (1959). Aqueous and organic
compounds were separated, analyzed, and quantified using liquid chromatography-
electrospray ionization-isotope dilution mass spectrometry (LC-ESI-IDMS), as previously
described (Koc et al., 2002), after spiking the samples with deuterium-labeled internal
standards which were used to correct for recovery. Results were expressed as nmol/mg DNA.
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For DEA determination in fetal brains and for the choline kinase assay described below, choline
(Cho, mass-to-charge ratio [m/z] 104), phosphocholine (PCho, m/z 184), DEA (m/z 106), and
phosphodiethanolamine (phospho-DEA [PDEA], m/z 186) were analyzed by monitoring the
mass of the intact cations using the method of Koc et al. (2002). Deuterium-labeled DEA (DEA-
d8) was used as the internal standard for quantitation of DEA. DEA had a linear response in
the 0−200 nmol range, and 100.3% recovery when spiked in a sample of cells. PCho-d9 was
used as the internal standard to calculate the ion peak intensity of PDEA, and to estimate the
concentration of PDEA due to the unavailability of an authentic PDEA standard. All
compounds were also analyzed in selected reaction monitoring mode to validate the data
collected in selected ion monitoring mode. Helium was used as the collision gas; relative
collision energy was set at 28% (Cho, DEA) and 30% (PCho, PDEA) of maximum, and dwell
time was set to 0.03 s for each transition. The most abundant product ion was used for
quantitation as follows: Cho at m/z 60, Cho-d9 at m/z 69, PCho at m/z 86, PCho-d9 at m/z 95,
DEA at m/z 88, DEA-d8 at m/z 96, and PDEA at m/z 88.
Choline kinase in vitro assay
Choline kinase (EC 2.7.1.32) was used as previously described (Goldberg and McCaman,
1973), to determine whether DEA could be phosphorylated to PDEA. Briefly, choline (0.5
μmol per reaction) and increasing amounts of DEA (0, 0.5, 2.5, 5, 10, 20 μmol per reaction),
in a total volume of 25 μl, was added to 0.5 ml cocktail containing 10mM MgCl2, 6.5mM
Glycyl-Glycine, pH 8.5, 4.25mM dithiotreitol, 0.33mM ATP, and 0.05 U choline kinase (yeast
origin C7138; Sigma) and incubated at 30°C for 15 min. The reaction was stopped with the
addition of 2.5 ml ice-cold H2O, and the samples were stored at − 20°C until analyzed for
choline, PCho, DEA, and PDEA. For this experiment, the molar ratio between DEA and choline
was 0:1, 1:1, 5:1, 10:1, 20:1, and 40:1, respectively. The highest ratio was similar to the DEA/
choline ratio used in the in vivo cell culture study (42:1). All reactions were performed in
duplicate.
Statistics
Statistical analysis was performed using JMP 3.2.6 software (SAS Institute Inc, Cary, NC).
One-way ANOVA was used to test the null hypothesis between all four treatments (CT, CS,
CT-DEA, and CS-DEA), and Tukey-Kramer critical difference test was used to determine the
statistical differences between these groups. Differences were considered significant at p value
< 0.05.
RESULTS
DEA in Fetal Brains
In fetal brains obtained from pups from two different dams, free DEA concentrations were
0.023 and 0.026mM, and PDEA concentrations were 1.6 and 1.3mM, respectively.
Cell Proliferation and Apoptosis
Exposure of mouse neural precursor cells to DEA (CT-DEA, 3mM) reduced the incorporation
of BrdU into cells after 48 and 72 h compared to CT (3.8% BrdU-positive cells ± 0.4 SE and
2.6% BrdU-positive cells ± 0.4 SE vs. 16.0% ± 1.1 SE and 15.4% ± 1.1 SE, respectively, Fig.
1a). CS-DEA almost completely restored BrdU incorporation at 48 h (11.7% ± 0.7 SE), and
completely restored it at 72 h (14.0% ± 0.3 SE) compared to CT. No differences were found
between CT and CS neural precursor cells. These results indicate that DEA inhibits BrdU
incorporation within 48 h exposure. Choline supplementation restores BrdU incorporation in
DEA-treated cells, suggesting that DEA inhibits cell proliferation by interfering with
availability of intracellular choline.
Niculescu et al. Page 4













Changes in rates of DNA fragmentation were observed at a later time point than were changes
in BrdU incorporation (Fig. 1b). At 48 h of DEA treatment, both CS- and CS-DEA-treated
cells had less DNA fragmentation than did CT cells (2.7% TUNEL-positive cells ± 0.3 SE and
3.5% TUNEL-positive cells ± 0.4 SE vs. 6.1% ± 0.3 SE). DEA (CT-DEA) did not induce a
significant increase in DNA fragmentation (5.5% ± 1.1 SE) compared to CT at this time. At
72 h, DEA (CT-DEA) induced a threefold increase (to 14.8% ± 2.2 SE) in DNA fragmentation
compared to CT (4.8% ± 0.2 SE), while CS-DEA prevented this increase (5.6% ± 0.4 SE).
These results suggest that DEA increases apoptosis by interfering with availability of
intracellular choline.
Choline Uptake
Uptake of radiolabeled choline into neural precursor cells was similar in CT and CS groups
(Fig. 2). Exposure to DEA decreased choline uptake to 51.9% of CT (p < 0.05). CS-DEA
prevented this effect.
Choline Metabolites
Concentrations of choline metabolites in neural precursor cells are indicated in Table 1. No
betaine was detected in any of the groups of cells. Choline supplementation increased
intracellular concentrations of choline and phosphocholine, but did not change concentrations
of other choline metabolites compared to CT. Exposure to DEA (CT-DEA) decreased
intracellular concentrations of choline and phosphocholine, but did not change concentrations
of other choline metabolites. CS-DEA prevented the decrease in choline concentrations, but
only partially prevented the decrease in phosphocholine concentrations; again all other choline
metabolites were unchanged.
Choline/DEA Competition Study
We observed that DEA was a substrate for choline kinase and that more PDEA was formed as
exposure to DEA was increased (Fig. 3a). In the presence of choline, choline kinase
phosphorylated DEA to PDEA in a dose-dependent manner. The curve shape suggests that
saturation levels of substrate were reached at 40 μmol/ml DEA or above. At the same time,
DEA inhibited phosphorylation of choline at the highest concentration (40 μmol/ml) (Fig. 3b).
DISCUSSION
We report, for the first time that neural precursor cells treated with 3mM DEA in vitro have
decreased cell proliferation and increased rates of apoptosis. The DEA concentration used in
the cell culture medium (3mM) is similar to the concentration of phosphorylated DEA in fetal
mouse brains (1.5mM; this underestimates total DEA compounds in brain) from dams treated
with DEA at concentrations that inhibited cell proliferation and increased apoptosis in fetal
hippocampus (Craciunescu et al., 2006). While changes in BrdU incorporation (cell
proliferation) were first noted at 48 h, increased apoptosis was a later event (72 h). Choline
supplementation of the DEA-containing media prevented DEA-induced changes in
proliferation and apoptosis. We also found that DEA treatment competes with choline transport
into neural precursor cells and that this effect can be overcome by addition of excess choline.
These data help to explain why DEA treatment during pregnancy resulted in changes in fetal
brain development that are similar to those observed when dams are choline deficient during
pregnancy (Craciunescu et al., 2006); DEA competes with choline for transport into cells. Our
results are consistent with previous reports of DEA's effects in other cell types. DEA
competitively inhibits choline uptake in both CHO-K1 cells and Syrian hamster embryo cells
(Lehman-McKeeman and Gamsky, 1999, 2000).
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We previously reported that phosphocholine was the metabolite most affected in mouse liver
after treatment with DEA in vivo (Lehman-McKeeman et al., 2002). It is interesting that,
although choline supplementation could restore intracellular concentrations of choline after
DEA treatment, it did not fully restore intracellular concentrations of phosphocholine. This
suggests that DEA, in addition to inhibiting choline transport, acts to change the flux of
phosphocholine either by inhibiting choline kinase or by accelerating the use of phosphocholine
for synthesis of phosphatidylcholine (Fig. 4). The latter mechanism is unlikely because DEA
is incorporated into the phospholipid fraction in liver and inhibits phosphatidylcholine
synthesis (Lehman-McKeeman and Gamsky, 1999). To determine whether DEA directly
inhibits choline phosphorylation, we incubated DEA with purified choline kinase. We found
that DEA was phosphorylated at a much lower rate than was choline, suggesting that choline
kinase has a very low affinity for DEA, compared to choline. This conclusion is supported by
previous studies that indicated that choline kinase has a higher Km for DEA (12mM) than it
does for either choline (Km = 0.076mM) or ethanolamine (Km = 0.054mM) for the synthesis
of phospholipids in vitro (Barbee and Hartung, 1979). Despite this, using a similar ratio of
DEA/choline as in our in vivo study (40:1, see the “Materials and Methods” section), we found
that choline phosphorylation was significantly inhibited in the presence of DEA. It is not
surprising that DEA treatment did not alter concentrations of phosphatidylcholine (or of
glycerophosphocholine which is a breakdown product of phosphatidylcholine, Fig. 4) and
sphingomyelin, as the 48-h duration of the experiment was short relative to the rate of turnover
of these phospholipids in neural precursor cells.
As noted earlier, DEA is a commonly used ingredient in consumer products. However, no
human data are available at the present to allow accurate assessment of DEA exposure, and
there is no data on DEA metabolite concentrations in human tissues. Therefore, it is impossible
to determine whether the various dosages used in animal studies accurately reflect human
exposure (TPMC, 2002). Previous studies using rats and mice show that daily DEA
administration dermally, intravenously, or orally results in DEA accumulation in various
tissues (Mathews et al., 1997; TPMC, 2002). Repeated daily administration of 7 mg DEA/kg
bw in rats generated DEA concentrations in rat brain between 0.17mM (2-week exposure) and
0.29mM (8-week exposure) (Mathews et al., 1997). In our study, DEA administration to
pregnant mice for 10 days (80 mg/kg bw daily) generated PDEA concentrations of about 1.3
to 1.5mM, indicating that DEA accumulated in fetal tissues and that the DEA concentration
we used in the culture medium was appropriate.
Our work suggests that DEA interferes with choline transport and choline phosphorylation in
neural precursor cells and this may explain the previously reported effects of DEA on brain
development (Craciunescu et al., 2006). Moreover, because choline supplementation can
overcome the observed effects of DEA, we suggest that DEA acts by altering intracellular
choline availability. We previously established that choline deficiency altered the epigenetic
regulation of gene expression in cell culture and in fetal brain by inhibiting DNA methylation,
thereby changing expression of cyclin-dependent kinase inhibitors that modulate cell
proliferation (Niculescu et al., 2004, 2006). We suggest that the same mechanism may be
involved in the DEA-induced outcomes. This hypothesis is also supported by a recent study
showing that both choline deficiency and DEA alter the DNA methylation profile in mouse
livers (Bachman et al., 2006). We can only speculate about the effects of DEA exposure on
brain development. Mouse fetuses born of dams fed a choline deficient diet have permanent
alterations in memory and attention (Meck and Williams, 2003). Whether or not these findings
can be applied to the human brain development remains to be determined.
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DEA altered BrdU incorporation and apoptosis in mouse neural progenitor cells from
embryonic day 14. Neural precursor cells were cultured in Neurobasal medium (see the
“Materials and Methods” section) containing 70μM choline (CT), 70μM choline, and 3mM
DEA (CT-DEA); 210μM choline (CS); or 210μM choline and 3mM DEA (CS-DEA). Cell
proliferation and apoptosis were assessed after 48 and 72 h, using BrdU incorporation and
TUNEL, respectively. Results are expressed as percentage of cells that are BrdU or TUNEL
positive. Error bars indicate SE. Superscripts denote statistical significance at p < 0.05: *,
different than all other groups; a, different than CT; b, different than CS; c, different than CT-
DEA. Arrows show significance of change for the same treatment and between time points.
(a) BrdU incorporation at 48 and 72 h exposure. (b) DNA fragmentation at 48 and 72 h
exposure.
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DEA inhibited choline uptake in mouse neural precursor cells from embryonic day 14. Neural
precursor cells were cultured in Neurobasal medium (see the “Materials and Methods” section)
containing 70μM choline (CT), 70μM choline, and 3mM DEA (CT-DEA); 210μM choline
(CS); or 210μM choline and 3mM DEA (CS-DEA). All plates were treated with the same
amount of radiolabeled choline. After 6 h of exposure, cells were harvested and intracellular
choline uptake was measured. An asterisk denotes statistical significance compared to all other
groups at p < 0.05 (Tukey-Kramer). Error bars indicate SE.
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DEA inhibited choline phosphorylation by choline kinase. Increased amounts of DEA (0, 1,
5, 10, 20, or 40 μmol/ml per reaction) were incubated in the presence of choline kinase and 1
μmol/ml choline (see the “Materials and Methods” section). An asterisk denotes statistical
significance versus all other groups; a, different from all other groups except the 20 μmol/ml
DEA dose; b, different than all other groups except the 10 μmol/ml DEA dose (p < 0.05, Tukey-
Kramer). PDEA, phospho-DEA; PCho, phosphocholine. Error bars indicate SE. (a) DEA
phosphorylation by choline kinase assay. (b) Choline phosphorylation by choline kinase assay.
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Choline metabolism (selected pathways). Metabolism of choline intersects with the
homocysteine metabolism. Choline is phosphorylated to phosphocholine by choline kinase in
the first step toward phosphatidylcholine synthesis. In an alternate pathway, choline serves as
a methyl donor (through betaine) for the methylation of homocysteine to methionine.
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